Press Releases

Year

September 19, 2023

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass. , Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the grant of inducement equity awards to Emily Hill, the Company’s newly

September 19, 2023

Replimune Announces Appointment of Emily Hill as Chief Financial Officer

WOBURN, Mass. , Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer. Ms.

August 3, 2023

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo ® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License Application submission anticipated in Q1/2 2024 Cost sharing collaboration in cutaneous squamous

August 1, 2023

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present

July 31, 2023

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

Initial study in the neoadjuvant setting designed to assess RP1 in combination with the small molecule, oral PD-L1 inhibitor, INCB99280 WOBURN, Mass. & WILMINGTON, Del. --(BUSINESS WIRE)--Jul. 31, 2023-- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the

July 20, 2023

Replimune Announces Sander Slootweg will Depart from its Board of Directors

WOBURN, Mass. , July 20, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Sander Slootweg , founder and managing partner at Forbion, will not

June 6, 2023

Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting

Single agent RP1 showed meaningful anti-tumor activity, with an overall response rate of 27.3% (all complete responses) in evaluable patients, with all responses ongoing to date WOBURN, Mass. , June 06, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology

June 5, 2023

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

WOBURN, Mass. , June 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced the appointment of Veleka R.

June 3, 2023

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no progression in responding patients since the data snapshot presented in December 2022 Overall response rate

June 1, 2023

Replimune to Present at the Jefferies Global Healthcare Conference

WOBURN, Mass. , June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present in

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 19

Print Page

RSS Feeds RSS Feeds

Email Alerts Email Alerts

Contact IR Contact IR

Search Search